# Executive Summary: Closed-Loop Infusion Platform

## Purpose

This project is building a safer, smarter infusion platform for vasopressor therapy. The goal is to help care teams keep blood pressure in range by combining:

- pump control software,
- bedside decision support,
- centralized monitoring,
- and structured safety controls.

The program is progressing as an engineering and validation effort. It is not yet approved for patient-care deployment.

## Current Status (February 2026)

The platform now operates as a **secure integration baseline** in development:

- Core backend services are running together in a local environment.
- Device-like telemetry can be sent through a secure path with certificate-based transport.
- Access controls are enforced for users and simulated devices.
- A web UI supports key workflows (patients, sessions, devices, drug library, and model registry actions).
- The ML pipeline can generate a model package and automatically register version metadata in the backend registry.

In short: the system is now suitable for integrated engineering testing and demonstration under controlled conditions.

## What Works Today

### 1) Secure data path for development

- Telemetry from edge workflows can run over encrypted channels.
- Device API keys are enforced at ingestion.
- Automated self-test scripts validate the local secure bootstrap path.

### 2) End-to-end demo workflow

- Synthetic data generation is available for repeatable testing.
- The pipeline can train and evaluate a baseline model.
- Training output includes deploy-ready model artifacts and a manifest.
- Model metadata can be posted to the API registry in the same command flow.

### 3) Operator/developer visibility

- A React UI is integrated with the current API routes.
- Tab-based workflows simplify demo and integration usage.
- Local auth token fallback supports development workflows without external identity setup.

### 4) Safety and governance scaffolding

- Safety-controller logic and test structure are in place.
- Technical debt and traceability gap reporting are automated.
- Regulatory and validation document sets are organized and actively maintained.

## What Is Not Complete Yet

The largest remaining gaps are program-completion items, not basic integration items:

- Full hardware completion for all firmware/HAL pathways.
- Production-grade key and certificate lifecycle operations.
- Full system and hardware-in-the-loop verification evidence.
- Completion and approval of all regulatory package elements.

These are mandatory before any clinical release or real-world patient use.

## Risk and Control Posture

Current risk posture is **managed for development**, not for production:

- Strong direction on secure transport and access control is in place.
- Repeatable synthetic workflows reduce demo/test variability.
- Remaining high-impact risks are tied to production hardening and formal evidence closure.

Open items are tracked in the technical debt register, anomaly report, and validation traceability reports.

## Recommended Near-Term Priorities (Next 1–2 Quarters)

1. Complete hardware-path implementation and close firmware integration gaps.
2. Finalize production security operations (PKI lifecycle, key rotation, secret distribution).
3. Execute and document system/HIL verification against release criteria.
4. Close traceability and evidence gaps needed for design-control and regulatory readiness.

## Executive Bottom Line

The program has crossed from component-level prototyping into a credible integrated development baseline with secure telemetry and automated model packaging/registration workflows. It is progressing in the right direction, but it is **not yet release-ready**. Final readiness depends on hardware completion, production security operations, full verification evidence, and regulatory closure.
